Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes

Drug Metabolism and Disposition

Volumn 40, Issue 2, 2012, Pages 267-275

  Hutzler, J Matthew ^a   Yang, Young Sun ^a   Albaugh, Daniel ^a   Fullenwider, Cody L ^a   Schmenk, Jennifer ^a   Fisher, Michael B ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ALDEHYDE OXIDASE; CARBAZERAN; DRUG METABOLITE; FALNIDAMOL; HYDRALAZINE; HYDROGEN; LIVER EXTRACT; OXYGEN 18; UNCLASSIFIED DRUG; XK 469; ZALEPLON;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYOPRESERVATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG OXIDATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER CLEARANCE; LIVER METABOLISM; MASS SPECTROMETRY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ALDEHYDE OXIDASE; ALGORITHMS; ANIMAL USE ALTERNATIVES; CELLS, CULTURED; CRYOPRESERVATION; CYTOSOL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ENZYME STABILITY; HEPATOCYTES; HUMANS; HYDRALAZINE; INTESTINES; KINETICS; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

EID: 84862909119     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042861     Document Type: Article

References (32)

1. Akabane T, Tanaka K, Irie M, Terashita S, and Teramura T (2011) Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372-384.
2. Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, and LoRusso PM (2007) A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs 25:147-154. (Pubitemid 46020873)
3. Al-Salmy HS (2001) Individual variation in hepatic aldehyde oxidase activity. IUBMB Life 51:249-253.
4. Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, and Ivy SP (2005) Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxaliny-l) oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemother Pharmacol 56:351-357. (Pubitemid 41095397)
5. Baer BR, Wienkers LC, and Rock DA (2007) Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954-964. (Pubitemid 47035350)
6. Beedham C (1987) Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24:85-127.
7. Beedham C, Bruce SE, Critchley DJ, al-Tayib Y, and Rance DJ (1987) Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 12:307-310. (Pubitemid 18058717)
8. Diamond S, Boer J, Maduskuie TP Jr, Falahatpisheh N, Li Y, and Yeleswaram S (2010) Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285.
9. Dittrich Ch, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, and Fumoleau P (2002) Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38:1072-1080. (Pubitemid 34468012)
10. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, and Ratain MJ (1998) O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 16:1803-1810.
11. Duley JA, Harris O, and Holmes RS (1985) Analysis of human alcohol- and aldehyde-metabolizing isozymes by electrophoresis and isoelectric focusing. Alcohol Clin Exp Res 9:263-271. (Pubitemid 15011403)
12. Garattini E and Terao M (2011) Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 43:374-386.
13. Garattini E, Fratelli M, and Terao M (2008) Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019-1048.
14. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
15. Matthew Hutzler J, Linder CD, Melton RJ, Vincent J, and Scott Daniels J (2010) In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase. Drug Metab Dispos 38:1113-1121.
16. Johnson C, Stubley-Beedham C, and Stell JG (1985) Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem Pharmacol 34:4251-4256. (Pubitemid 16204474)
17. Kaye B, Offerman JL, Reid JL, Elliott HL, and Hillis WS (1984) A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14:935-945. (Pubitemid 15198638)
18. Kaye B, Rance DJ, and Waring L (1985) Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica 15:237-242. (Pubitemid 15050132)
19. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
20. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, and Scatina JA (2002) Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32:835- 847.
21. Obach RS (2000) Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 28:1069-1076.
22. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
23. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
24. Obach RS, Huynh P, Allen MC, and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19. (Pubitemid 38005089)
25. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
26. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, Scatina JA, and Lake BG (2002) Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 32:849-862. (Pubitemid 35155520)
27. Rosen AS, Fournié P, Darwish M, Danjou P, and Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20:171-175. (Pubitemid 29137676)
28. Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, and Dolan ME (1995) Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol 50:1385-1389.
29. Sahi J, Khan KK, and Black CB (2008) Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2:176 -183.
30. Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, and van Meel JC (2004) Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther 311:502-509. (Pubitemid 39391534)
31. Zhang X, Liu HH, Weller P, Zheng M, Tao W, Wang J, Liao G, Monshouwer M, and Peltz G (2011) In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11:15-24.
32. Zientek M, Jiang Y, Youdim K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327.